Bin Abdul Hamid Muhammad Azrul's Form 4 filing
BioNexus Gene Lab Corp (BGLC) · filed Aug 14, 2026
- Accession no.
- 0001520138-26-000347
- Filed
- Aug 14, 2026, 5:18 PM ET
- Trade date
- Aug 13, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bin Abdul Hamid Muhammad AzrulCIK 0002141872 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Common Shares | AGrant or awardAcquired | +32,258 | –F1 | – | 32,258 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).
Referenced by the price of 1 transaction in Table I.